Crystal Pharmaceutical (Suzhou) Co., Ltd. is full subsidiary of Crystal Pharmatech. It is headquartered in Suzhou, China with strategic R&D centers in Beijing, China and Toronto, Canada. It is aimed to become the best first-to-file (FTF) generic and 505B2 drug product development company using a combination of novel polymorph and formulation technologies. Through its partnership with leading API manufacturers and generic drug companies in the world, Crystal Pharmaceutical has successfully supported 8 FTF ANDAs containing Paragraph IV certifications and using novel polymorph technologies. Up to date, it has discovered and developed commercially viable novel polymorph technologies for over 70 marketed drug compounds. It has become the preferred novel polymorph and formulation technology partner for 5 out of the top 10 generic drug companies in the world.